Sumitomo Dainippon Pharma Co. Ltd. (4506.T) reported its Q4 2025 earnings, showcasing a significant earnings surprise with an EPS of -2.04, far exceeding the forecasted -15.24. Revenue reached 105.55 billion JPY, surpassing expectations of 103.62 billion JPY.
Despite this positive performance, the stock saw a slight decline of 1.44%, closing at 1,734 JPY, possibly due to broader market conditions.
Sumitomo Pharma demonstrated a remarkable turnaround in FY 2025, achieving record-high profitability despite previous challenges. The company reported a 13.7% year-over-year increase in total revenue, driven by strong performance in the U.S. market.
For FY 2026, Sumitomo Pharma projects a slight decline in gross profit margin to 54.6%. The company remains optimistic about its growth drivers, particularly ORGOVYX and GEMTESA, with strategic expansions planned in the oncology segment.
